Cerebrolysin

Cerebrolysin (developmental code name FPF-1070) is a mixture of peptides purified from pig brains, including (and not limited to) brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).[1][2]

While cerebrolysin is used for stroke[3] and vascular dementia, the evidence to support this use is weak.[4] It is also sold as a nootropic.

There is some tentative evidence of a beneficial effect on cognitive function in people with vascular dementia,[4] possibly through decreased beta-amyloid deposition.[5] Cerebrolysin is widely used in Russia, Eastern Europe, China, and other post-Soviet and Asian countries.[3]


References

  1. Windisch M, Gschanes A, Hutter-Paier B (1998). "Neurotrophic activities and therapeutic experience with a brain derived peptide preparation". J. Neural Transm. Suppl. Journal of Neural Transmission. Supplementa. 53: 289–98. doi:10.1007/978-3-7091-6467-9_25. ISBN 978-3-211-83114-4. PMID 9700665.
  2. Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS (2012). "Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals". CNS Neurol Disord Drug Targets. 11 (1): 40–9. doi:10.2174/187152712799960781. PMID 22229324.
  3. Ziganshina, Liliya Eugenevna; Abakumova, Tatyana; Hoyle, Charles Hv (14 July 2020). "Cerebrolysin for acute ischaemic stroke". The Cochrane Database of Systematic Reviews. 7: CD007026. doi:10.1002/14651858.CD007026.pub6. ISSN 1469-493X. PMC 7387239. PMID 32662068.
  4. Cui, Shuhui; Chen, Ning; Yang, Mi; Guo, Jian; Zhou, Muke; Zhu, Cairong; He, Li (11 November 2019). "Cerebrolysin for vascular dementia". The Cochrane Database of Systematic Reviews. 2019 (11). doi:10.1002/14651858.CD008900.pub3. ISSN 1469-493X. PMC 6844361. PMID 31710397.
  5. Masliah E, Díez-Tejedor E (2012). "The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders". Drugs Today. 48 Suppl A: 3–24. doi:10.1358/dot.2012.48(Suppl.A).1739716 (inactive 2021-01-10). PMID 22514792.CS1 maint: DOI inactive as of January 2021 (link)


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.